PortfoliosLab logoPortfoliosLab logo
Shuttle Pharmaceuticals Inc (SHPH)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date
Aug 31, 2022

Highlights

EPS (TTM)
-$6.37
Gross Profit (TTM)
-$2.80K
EBITDA (TTM)
-$10.72M
Year Range
$0.50 - $13.63
ROA (TTM)
-102.19%
ROE (TTM)
-474.85%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Shuttle Pharmaceuticals Inc

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Shuttle Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Shuttle Pharmaceuticals Inc (SHPH) has returned -62.29% so far this year and -93.02% over the past 12 months.


Shuttle Pharmaceuticals Inc

1D
26.88%
1M
-32.12%
YTD
-62.29%
6M
-80.88%
1Y
-93.02%
3Y*
-86.33%
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Aug 31, 2022, SHPH's average daily return is -0.64%, while the average monthly return is -14.28%.

Historically, 35% of months were positive and 65% were negative. The best month was Oct 2024 with a return of +40.6%, while the worst month was Sep 2022 at -88.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, SHPH closed higher 43% of trading days. The best single day was Sep 6, 2022 with a return of +91.3%, while the worst single day was Sep 2, 2022 at -71.6%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202612.22%-50.50%-32.12%-62.29%
2025-12.34%-19.15%-36.10%-31.26%-34.63%-13.84%-3.05%-9.59%7.58%-16.34%-51.85%25.87%-91.62%
2024-14.22%0.31%3.70%0.27%30.43%-24.71%0.03%-39.67%-31.09%40.60%-54.65%1.30%-76.40%
2023-5.10%1.08%-29.26%24.06%-32.68%3.54%-21.73%-17.80%-17.56%-23.11%6.59%-8.98%-76.79%
2022-88.07%-42.92%-44.66%35.17%-94.91%

Benchmark Metrics

Shuttle Pharmaceuticals Inc has an annualized alpha of -82.00%, beta of 0.60, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 01, 2022.

  • This stock participated in 292.99% of S&P 500 Index downside but only -168.47% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.60 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-82.00%
Beta
0.60
0.01
Upside Capture
-168.47%
Downside Capture
292.99%

Return for Risk

Risk / Return Rank

SHPH ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


SHPH Risk / Return Rank: 77
Overall Rank
SHPH Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
SHPH Sortino Ratio Rank: 22
Sortino Ratio Rank
SHPH Omega Ratio Rank: 44
Omega Ratio Rank
SHPH Calmar Ratio Rank: 33
Calmar Ratio Rank
SHPH Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Shuttle Pharmaceuticals Inc (SHPH) and compare them to a chosen benchmark (S&P 500 Index).


SHPHBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.74

0.90

-1.63

Sortino ratio

Return per unit of downside risk

-1.93

1.39

-3.32

Omega ratio

Gain probability vs. loss probability

0.77

1.21

-0.44

Calmar ratio

Return relative to maximum drawdown

-0.98

1.40

-2.38

Martin ratio

Return relative to average drawdown

-1.30

6.61

-7.91

Explore SHPH risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Shuttle Pharmaceuticals Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Shuttle Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Shuttle Pharmaceuticals Inc was 99.99%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Shuttle Pharmaceuticals Inc drawdown is 99.99%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Sep 2, 2022895Mar 30, 2026

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Shuttle Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Shuttle Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items